Fentanyl

ROSWELL, NM, UNITED STATES, May 7, 2026 / EINPresswire.com / -- Renew Health Addiction Recovery Services, a leading provider of outpatient and telehealth behavioral health services, is announcing the expansion of its online addiction treatment programs across New Mexico. This initiative aims to increase access to life-saving care as the state continues to face rising overdose rates and a significant demand for accessible recovery resources. Renew Health operates physical clinic locations in Roswell, Alamogordo, and Clovis, providing a foundation for its comprehensive hybrid care model. By expanding its telehealth infrastructure, the organization is now able to deliver specialized substance abuse treatment to residents in rural and underserved areas who previously faced geographical barriers to quality care. "The expansion of our telehealth services is a critical step in meeting New Mexicans where they are," said a spokesperson for Renew Health Addiction Recovery Services. "By integrating online addiction treatment programs with our established outpatient clinics, we are removing the obstacles of travel and scheduling, ensuring that professional support is available to anyone in the state struggling with substance use disorders." According to recent health data, New Mexico has consistently experienced overdose mortality rates higher than the national average. In response, Renew Health has tailored its programs to address the specific needs of the region, offering a full spectrum of services for alcohol and drug dependency, including: ⏺ Medication-Assisted Treatment (MAT): Utilizing FDA-approved medications to support recovery from opioids and alcohol. ⏺ Intensive Outpatient Programs (IOP): Structured therapy that allows patients to maintain their daily responsibilities while receiving high-level care. ⏺ Withdrawal Management: Clinical oversight for those navigating the early stages of detox. ⏺ Specialized Opioid Treatment: Dedicated protocols for heroin, prescription opioids, and fentanyl addiction. The telehealth platform provides patients with secure, HIPAA-compliant access to licensed therapists and medical professionals. This service includes individual counseling, group therapy, and psychiatric support, mirroring the evidence-based care provided at their physical locations, such as the Roswell, NM facility and the Clovis, NM clinic. Renew Health’s approach emphasizes long-term wellness by treating the "whole person." This includes addressing co-occurring mental health disorders that often accompany addiction. "Our goal is not just sobriety, but the restoration of health and purpose," the spokesperson added. "Expanding our digital reach allows us to provide consistent, stable support systems for patients throughout their entire recovery journey." For more information about the online addiction treatment programs or to find a local clinic in Alamogordo or the surrounding areas, please visit https://renewhealth.com . About Renew Health Addiction Recovery Services Renew Health Addiction Recovery Services is a top-rated alcohol and drug addiction treatment center in New Mexico. Specializing in both online telehealth services and outpatient rehabilitation, Renew Health provides comprehensive care for a variety of substance use disorders, including opioids, meth, cocaine, and alcohol. With a mission to provide accessible, evidence-based treatment, Renew Health operates clinics in Roswell, Alamogordo, and Clovis while serving the entire state through its advanced telehealth platform. Trent Carter Renew Health +1 575-363-4357 email us here Visit us on social media: Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

CAMBRIDGE, Mass., May 5, 2026 /PRNewswire/ -- Clear Scientific Inc., a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted its lead asset, CS-1103, Fast Track designation for treatment of acute fentanyl intoxication. Clear Scientific is focused on the development of first-in-class small molecules to reverse acute intoxication from drugs of abuse and accelerate their clearance from the body, preventing further harm. The FDA grants investigational medicines Fast Track designation to facilitate the development and expedite the review of medicines that demonstrate the potential to treat serious conditions and fill an unmet medical need. CS-1103 is an injectable therapeutic that, in non-clinical studies, binds and encapsulates intoxicants in the blood, rapidly reversing their toxic effects. Subsequently, CS-1103 accelerates the clearance of the intoxicants into urine, preventing further harm. CS-1103 was shown to be safe and well tolerated in humans at clinically relevant doses in a Phase 1 clinical trial . Phase 2 trials for Fentanyl are expected to begin in June 2026. "There are substantial gaps in current overdose and detox treatments for opioids. Based on non-clinical studies, CS-1103, administered alongside naloxone, can greatly increase the safety of acute intoxication scenarios, by preventing renarcotization. In addition, CS-1103 has the potential to improve rapid and safe transition to addiction treatments, particularly buprenorphine, through its ability to remove virtually all the opioids from the body in a short period of time. Receiving the Fast Track designation for CS-1103 for fentanyl is an important milestone for our company. This designation facilitates the review process, shortening the clinical development timeline." Shekar Shetty CEO. About the Opioid Crisis: Opioids cause 2,500 emergency department visits and 150 deaths daily in the US. In 2024, synthetic opioids were associated with more than 55,000 fatalities and according to the White House, the fentanyl-fueled opioid crisis cost the U.S. economy nearly $2.7 trillion in 2023 —impacting healthcare, criminal justice, and productivity in every community. Fentanyl | Overdose Prevention | CDC About Clear Scientific Clear Scientific was co-founded in March 2019 by Professor George M. Whitesides of Harvard University with technology licensed from Massachusetts General Hospital and the University of Maryland. Clear Scientific is pioneering a new paradigm for treatment of conditions and diseases that involve an excess of specific compounds in the body. The company is developing highly selective, small molecule sequestrants that bind, inactivate, and rapidly clear these excess compounds from the body. Clear Scientific receives funding from the National Institutes of Health (NIH) / National Institute on Drug Abuse (NIDA) and is working with their network of medical and academic professionals. Research reported in this press release was supported by the National Institute on Drug Abuse of the National Institutes of Health under award number UG3DA059286. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. For more information, visit SOURCE Clear Scientific, Inc. 21% more press release views with Request a Demo